GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nemaura Medical Inc (OTCPK:NMRD) » Definitions » ROA %

Nemaura Medical (Nemaura Medical) ROA %

: -122.71% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Nemaura Medical's annualized Net Income for the quarter that ended in Dec. 2023 was $-8.64 Mil. Nemaura Medical's average Total Assets over the quarter that ended in Dec. 2023 was $7.04 Mil. Therefore, Nemaura Medical's annualized ROA % for the quarter that ended in Dec. 2023 was -122.71%.

The historical rank and industry rank for Nemaura Medical's ROA % or its related term are showing as below:

NMRD' s ROA % Range Over the Past 10 Years
Min: -139.04   Med: -41.38   Max: -18.1
Current: -106.37

During the past 10 years, Nemaura Medical's highest ROA % was -18.10%. The lowest was -139.04%. And the median was -41.38%.

NMRD's ROA % is ranked worse than
91.46% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -1.64 vs NMRD: -106.37

Nemaura Medical ROA % Historical Data

The historical data trend for Nemaura Medical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.82 -139.04 -34.33 -48.43 -77.15

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.56 -136.11 -90.49 -55.41 -122.71

Competitive Comparison

For the Medical Devices subindustry, Nemaura Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nemaura Medical ROA % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's ROA % distribution charts can be found below:

* The bar in red indicates where Nemaura Medical's ROA % falls into.



Nemaura Medical ROA % Calculation

Nemaura Medical's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=-14.144/( (22.102+14.563)/ 2 )
=-14.144/18.3325
=-77.15 %

Nemaura Medical's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-8.644/( (8.919+5.169)/ 2 )
=-8.644/7.044
=-122.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Nemaura Medical  (OTCPK:NMRD) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-8.644/7.044
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-8.644 / 0)*(0 / 7.044)
=Net Margin %*Asset Turnover
=N/A %*0
=-122.71 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Nemaura Medical ROA % Related Terms

Thank you for viewing the detailed overview of Nemaura Medical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nemaura Medical (Nemaura Medical) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.
Executives
Bashir Timol director, 10 percent owner, officer: Chief Business Officer C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Chowdhury Dewan Fazlul Hoque director, 10 percent owner, officer: CEO & President CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ
Salim Natha director LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Justin James Mclarney officer: Chief Financial Officer C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Sufyan Ismail 10 percent owner C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Thomas Peter Moore director C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Timothy Christopher Johnson director C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Iain Anderson officer: CFO LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Kathryn Farrar officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Julie Pomeroy officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Richard Toon officer: Technical & Bus. Dev. Manager C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT

Nemaura Medical (Nemaura Medical) Headlines

From GuruFocus

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

By Stock market mentor Stock market mentor 01-11-2023

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

By Stock market mentor Stock market mentor 01-26-2023